Table 1.

CLEOPATRA: Cardiac tolerability^a

	Placebo + trastuzumab + docetaxel	Pertuzumab + trastuzumab + docetaxel
n	397	407
Investigator-assessed symptomatic LVSDb	1.8%	1.0%
Independently adjudicated symptomatic LVSDb	1.0%	1.0%
Fall in LVEF to < 50% or by ≥ 10% points from baseline	6.6%	3.8%

LVEF = left ventricular ejection fraction

LVSD = left ventricular systolic dysfunction.

^aAdapted from Baselga J et al. [40].

^bSymptomatic LVSD was defined as New York Heart Association (NYHA) class III/IV.